This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

At One Month Post-Launch, More Than One-Quarter Of Surveyed U.S. Medical Oncologists Have Prescribed Boehringer Ingelheim's Gilotrif For Non-Small-Cell Lung Cancer

EXTON, Pa., Dec. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, one month post-launch in the United States, more than a quarter of surveyed U.S. medical oncologists have prescribed Boehringer Ingelheim's irreversible epidermal growth factor receptor (EGFR) inhibitor Gilotrif for the treatment of non-small-cell lung cancer (NSCLC). According to the first wave of the LaunchTrends® Gilotrif report series, approximately three-quarters of current Gilotrif nonprescribers expect to prescribe Gilotrif to their treatment-naive, EGFR mutation-positive metastatic NSCLC patients within the next six months.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The report also finds that over half of surveyed medical oncologists reported high favorability towards Gilotrif, and nearly two-thirds indicated a high interest level in learning more about the product. However, Gilotrif fails to significantly differentiate itself from Genentech/Roche/Chugai/Astellas' Tarceva for the treatment of EGFR mutation-positive NSCLC patients in the first-line setting over most key metrics, including efficacy and tolerability attributes. Notably, the availability of Tarceva is one of the top reasons limiting use of Gilotrif in this indication, along with lack of familiarity with Gilotrif and cost.

"We also find that medical oncologists are moderately to highly interested in prescribing Gilotrif in new, additional patient populations and hope to see regulatory approval in these indications, including the EGFR mutation-positive, EGFR TKI pretreated patient population and for patients harboring other EGFR mutations, including those associated with resistance to Tarceva (e.g. T790M mutations)," said Decision Resources Group Business Insights Analyst Orestis Mavroudis-Chocholis, Ph.D. "Similarly, surveyed medical oncologists report that they are most likely to prescribe Gilotrif in these patient populations over other available therapies, including Tarceva and chemotherapy regimens."

About BioTrends Research GroupBioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources GroupDecision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at  www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group Christopher Comfort781-993-2597 ccomfort@dresources.com

SOURCE BioTrends Research Group

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,888.38 +60.63 0.34%
S&P 500 2,072.42 -0.41 -0.02%
NASDAQ 4,807.7420 +20.4250 0.43%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs